Journal article
Synthesis and biological activity of isoprenoid bisphosphonates
Bioorganic & medicinal chemistry, Vol.14(12), pp.4130-4136
2006
DOI: 10.1016/j.bmc.2006.02.010
PMID: 16517172
Abstract
Bisphosphonates have been used in the clinic to treat osteoporosis and to reduce bone resorption and the accompanying pathological bone fractures that attend a number of malignancies including multiple myeloma and cancers of the prostate, breast, and lung. There is also evidence that some bisphosphonates have direct anticancer activity. Expansion of the current class of bisphosphonates may lead to compounds that more selectively and potently target these cancers through inhibition of the mevalonate pathway. To this end, a set of dialkyl bisphosphonates bearing isoprenoid chains of varying lengths has been synthesized. Some of these compounds were found to have biological activity on post-translational processing of the oncogenic small GTPases, Ras and Rap1a, in human-derived K562 leukemia cells. Most importantly, these compounds impair protein geranylgeranylation and not protein farnesylation.
Details
- Title: Subtitle
- Synthesis and biological activity of isoprenoid bisphosphonates
- Creators
- Larry W Shull - Department of Chemistry, University of Iowa, Iowa City, IA 52242-1294, USAAndrew J Wiemer - Interdisciplinary Program in Molecular Biology, University of Iowa, Iowa City, IA 52242-1294, USARaymond J Hohl - Department of Internal Medicine, University of Iowa, Iowa City, IA 52242-1294, USADavid F Wiemer - Department of Chemistry, University of Iowa, Iowa City, IA 52242-1294, USA
- Resource Type
- Journal article
- Publication Details
- Bioorganic & medicinal chemistry, Vol.14(12), pp.4130-4136
- Publisher
- Elsevier Ltd
- DOI
- 10.1016/j.bmc.2006.02.010
- PMID
- 16517172
- ISSN
- 0968-0896
- eISSN
- 1464-3391
- Language
- English
- Date published
- 2006
- Academic Unit
- Neuroscience and Pharmacology; Chemistry; Internal Medicine
- Record Identifier
- 9983985805802771
Metrics
13 Record Views